Consolidation Whole Abdominal Intensity-Modulated Radiation Therapy (IMRT) in Advanced Ovarian Cancer

Consolidation Intensity-Modulated Whole Abdominal Radiotherapy for High-Risk Patients With Ovarian Cancer Stage FIGO III

The primary objective of this phase-II study is to assess the toxicity of consolidation intensity-modulated whole-abdominal radiotherapy using tomotherapy in patients with advanced optimally debulked stage International Federation of Gynecology and Obstetrics (FIGO) III ovarian cancer with a complete remission after adjuvant chemotherapy.

36 patients will be treated to a total dose of 30 Gy in 1.5 Gy fractions. The planning target-volume includes the entire peritoneal cavity and the pelvic and para-aortal node regions. Intensity-modulated whole-abdominal radiotherapy allows an effective sparing of liver, kidneys and bone-marrow (vertebral bodies and pelvic bones).

Inclusion Criteria:

• histologically confirmed ovarian cancer or tube cancer or primary peritoneal carcinoma stage FIGO III
• primary optimal debulking surgery
• postoperative gross residual tumor ≤ 1cm ( R0, R1 oder R2 < 1cm situation)
• adjuvant chemotherapy with platin and taxane
• complete remission after chemotherapy
• Karnofsky performance score > 60
• patients >18 years of age
• written informed consent

Exclusion Criteria:

• stage FIGO I or II
• stage III with postoperative gross residual tumor > 1cm
• stage FIGO IV
• recurrence situation
• delayed wound healing post laparotomy
• leucopenia <2000/ml before radiotherapy
• thrombocytopenia <75000/ml before radiotherapy
• clinically active renal, hepatic, cardiac, metabolic, respiratory, coagulation or hematopoietic disease
• status post pelvic or abdominal radiotherapy
• status post other cancer disease in the past 5 years (cervical cancer in situ, basal cell carcinoma, squamous cell carcinoma of the skin are excluded)
• participation in another clinical trial